Flualprazolam

Flualprazolam is a benzodiazepine derivative which was first synthesised in 1976,[2] but was never marketed. It has subsequently been sold as a designer drug,[3][4][5] first being definitively identified in Sweden in 2018.[6][7] It can be described as the 2'-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.[8][9][10][11][12]

Flualprazolam
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H12ClFN4
Molar mass326.76 g·mol−1
3D model (JSmol)

Flualprazolam is banned in Sweden.[13] In December 2019, the World Health Organization recommended flualprazolam for international scheduling under the Convention on Psychotropic Substances.[14]

See also

References
  1. https://www.oregon.gov/pharmacy/Documents/Permanently_Adopted_TrackedChanges_Div_041_Div_080_BP_8-2020.pdf
  2. US 3987052, Hester JB, et al., "6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines."
  3. Wagmann L, Manier SK, Bambauer TP, Felske C, Eckstein N, Flockerzi V, Meyer MR (February 2020). "Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration, and main urinary excretion products". Journal of Analytical Toxicology. doi:10.1093/jat/bkaa019. PMID 32104896.
  4. Papsun, Donna M.; Krotulski, Alex J.; Homan, Joe; Temporal, Keith D. H.; Logan, Barry K. (June 2020). "Flualprazolam Blood Concentrations in 197 Forensic Investigation Cases". Journal of Analytical Toxicology. doi:10.1093/jat/bkaa070. PMID 32542312.
  5. Rice, Kathleen; Hikin, Laura; Lawson, Alexander; Smith, Paul R.; Morley, Stephen (August 2020). "Quantification of Flualprazolam in Blood by LC–MS-MS: A Case Series of Nine Deaths". Journal of Analytical Toxicology. doi:10.1093/jat/bkaa098. PMID 32780842.
  6. Svenska Narkotika Polisföreningens Tidskrift, June 1 2018
  7. Kriikku P, Rasanen I, Ojanperä I, Thelander G, Kronstrand R, Vikingsson S (February 2020). "Femoral blood concentrations of flualprazolam in 33 postmortem cases". Forensic Science International. 307: 110101. doi:10.1016/j.forsciint.2019.110101. PMID 31865266.
  8. Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S (May 2018). "The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines" (PDF). Science & Justice. 58 (3): 219–225. doi:10.1016/j.scijus.2017.12.004. PMID 29685303.
  9. Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466.
  10. Moosmann B, Auwärter V (October 2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances". Handbook of Experimental Pharmacology. Springer International Publishing. 252: 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10561-7. PMID 30367253.
  11. Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P (February 2018). "Les «designer benzodiazepines» : qu'en sait-on aujourd'hui ?". Toxicologie Analytique et Clinique. 30 (1): 5–18. doi:10.1016/j.toxac.2017.12.001. ISSN 2352-0078.
  12. Mei V, Concheiro M, Pardi J, Cooper G (October 2019). "Validation of an LC-MS/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood". Journal of Analytical Toxicology. 43 (9): 688–695. doi:10.1093/jat/bkz063. PMID 31436813.
  13. Riksdagsförvaltningen. "Förordning (1992:1554) om kontroll av narkotika". riksdagen.se (in Swedish).
  14. "News: December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling". www.unodc.org.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.